Evidence map›Paper›PMID 41607955›Full record

ArticleCureus2025

Safety of Post-transplant Cyclophosphamide as a Single Agent for Graft-Versus-Host Disease Prophylaxis After Human Leukocyte Antigen (HLA)-Matched Transplantation With the Japanese Population: A Single-Center Phase Ⅰ/Ⅱ Study.

Miki Joyce, Naoki Kurita, Bryan J Mathis, Kenichi Makishima, Sakurako Suma, Yuya Sasaki, Yasuhito Suehara, Keiichiro Hattori, Tatsuhiro Sakamoto, Takayasu Kato and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Miki JoyceDepartment of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, JPN.
Naoki KuritaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Bryan J MathisDepartment of Cardiovascular Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, JPN.
Kenichi MakishimaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Sakurako SumaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Yuya SasakiDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Yasuhito SueharaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Keiichiro HattoriDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Tatsuhiro SakamotoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Takayasu KatoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Naoshi ObaraDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Shigeru ChibaDepartment of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, JPN.
Hidekazu NishikiiDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.
Mamiko Sakata-YanagimotoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Graft-versus-host disease (GVHD) is a severe complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although calcineurin inhibitor (CNI)-containing GVHD prophylaxis is currently standard, it has the disadvantages of nephrotoxicity, a risk for thrombotic microangiopathy, drug interaction, and a requirement for monitoring blood concentration. Therefore, we conducted a prospective trial with the Japanese population undergoing allo-HSCT from an HLA-matched donor to investigate the safety and preliminary efficacy of single-agent post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis. Methods This single-center phase I/II trial was a prospective study registered in the UMIN Clinical Trials Registry (UMINID: UMIN000028779) on November 1, 2017, and enrolled patients aged 16-60 years old with hematological malignancies in remission but without a history of previous allo-HSCT. Myeloablative conditioning (fludarabine 120 mg/m

Indexed as

bone marrow stem cell transplantationcalcineurin inhibitorgraft-versus-host disease (gvhd)hla-matched donorpost-transplant cyclophosphamide

Identifiers

PMID41607955
PMCPMC12840819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.